DMAC — DiaMedica Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $97.55m
- $44.66m
- 42
- 26
- 64
- 40
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -10.6 | -12.3 | -13.6 | -13.7 | -19.4 |
Depreciation | |||||
Non-Cash Items | 1.14 | 1.89 | 1.78 | 1.55 | 0.53 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.387 | 1.2 | -0.461 | 0.585 | 0.093 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -9.1 | -9.19 | -12.3 | -11.5 | -18.7 |
Capital Expenditures | -0.002 | -0.047 | -0.022 | -0.081 | -0.024 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -3.91 | -16.1 | -20.5 | 11.6 | -18.3 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -3.91 | -16.1 | -20.5 | 11.5 | -18.3 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.07 | 28.8 | 30.1 | -0.006 | 36.8 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -12.9 | 3.53 | -2.7 | 0.021 | -0.185 |